Curated News:

NEJM

Add to Favorites | Subscribe | Share

Filters:

  • (Press "esc" to clear)

Medicine

Channels:

Stroke, Thrombectomy

Stroke Study Expands Window of Clot Removal Treatment for Some Patients

A procedure to remove clots from blocked brain vessels – known as thrombectomy - may be beneficial for some stroke patients even if they come in to the emergency room beyond the 6-hour treatment window that current guidelines endorse, according to a groundbreaking study conducted by an international team of physicians and researchers.

Medicine

Channels:

Cancer, Breast Cancer, Tamoxifen, Aromatase Inhibitor, endocrine therapy, ER-positive breast cancer, Breast Cancer Recurrence

Breast Cancer Recurrence Risk Lingers Years After Treatment Ends

37484850356_5302ca2301_o.jpg

Even 20 years after a diagnosis, women with a type of breast cancer fueled by estrogen still face a substantial risk of cancer returning or spreading, according to a new analysis from an international team of investigators published in the New England Journal of Medicine.

Medicine

Channels:

Kidney Disease, high-protein diet, Nephrology

UCI Review Points to Long-Term Negative Impact of High Protein Diets

High protein diets may lead to long-term kidney damage among those suffering from chronic chronic kidney disease, according to research led by nephrologist Kamyar Kalantar-Zadeh, MD, MPH, PhD, of the University of California, Irvine.

Medicine

Channels:

Spinal Muscular Atrophy, SMA, Treatment, Phase 3 clinical trial, spinraza, Children, Pediatric, FDA approved

Drug Improves Muscle Function and Survival in Spinal Muscular Atrophy

KuntzNancyNeuromuscularMedicine.JPG

More than half of the babies with infantile-onset spinal muscular atrophy (SMA) who were treated with nusinersen (Spinraza) gained motor milestones, compared to none of the babies in the control group. Infants treated with the drug also had 63 percent lower risk of death. These final results from the 13-month, international, randomized, multicenter, sham procedure-controlled, phase 3 trial called ENDEAR were published in the New England Journal of Medicine.

Medicine

Channels:

Adpkd, autosomal dominant polycystic kidney disease, Dr. Vicente Torres, Kidney, medical researech, Nephrology, PKD, Polycystic Kidney Disease, Tolvaptan, New England Journal Of Medicine

Vicente Torres, M.D., Ph.D., Discusses New Findings on Tolvaptan as Autosomal Dominant Polycystic Kidney Disease Treatment

A phase 3 trial studying the effects of tolvaptan has found that the drug slowed the rate of decline in kidney function in patients with the most common form of polycystic kidney disease, a condition with no cure.

Medicine

Channels:

Cystic Fibrosis, Cystic Fibrosis Foundation, ivacaftor, tezacaftor, chloride ions , Lung Disease

New Drug Combination Therapy for Cystic Fibrosis Shows Promise

Studies show a two-drug combination therapy for cystic fibrosis, using tezacaftor and ivacaftor, is effective. UAB researchers say triple combination therapy is close behind.

Medicine

Channels:

Interventional Cardiology, Cardiogenic Shock, PCI

Should Patients with Cardiogenic Shock Receive Culprit Lesion Only PCI or Multivessel PCI?

Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found that an initial strategy of culprit lesion only percutaneous coronary intervention (PCI) reduces the composite of 30-day mortality and/or severe renal failure in patients with multivessel disease and cardiogenic shock complicating acute myocardial infarction.

Medicine

Channels:

Interventional Cardiology, left main disease, PCI, CABG, Coronary Artery Bypass

Patients with Left Main Disease Treated with PCI or CABG Experience Significant and Similar Quality of Life Improvement after Three Years

New study results from the EXCEL trial comparing the quality of life (QoL) of patients with left main coronary artery disease (LMCAD) receiving percutaneous coronary intervention (PCI) versus coronary artery bypass graft surgery (CABG) found significant and similar QoL improvement at three years, although a greater benefit was observed with PCI at one month.

Medicine

Channels:

zika, Zika vaccine, Infectious Disease

Synthetic DNA-based Zika Vaccine Candidate Found to be Safe and Effective at Inducing Immune Response

A new generation DNA-based Zika vaccine is the first to demonstrate both safety and the ability to elicit an immune response against Zika in humans, according to new research from the Perelman School of Medicine at the University of Pennsylvania, conducted in partnership with The Wistar Institute, Inovio Pharmaceuticals, and GeneOne Life Science, Inc. In results published today in the New England Journal of Medicine, the phase 1 clinical trial showed for the first time that humans who received up to three doses of the vaccine candidate produced an immune response against Zika with minimal adverse effects, opening the door to further clinical trials for this important vaccine candidate.

Medicine

Channels:

Global Health

Mount Sinai Heart Director Valentin Fuster, MD, PhD, Provides Recommendations for Promoting Global Cardiovascular Health

Co-Chair of Consensus Committee Advising Trump Administration on Global Health Outlines How the United States Can Bolster Its Global Health Efforts







Chat now!